Introduction
Gastric cancer is among the deadliest epithelial malignancies with 5-year survival rates of approximately 24% (Van Cutsem et al., 2006) . Its high-mortality rates reflect the prevalence of advanced disease at presentation, aggressive biology despite the lack of symptoms at an early stage and relatively poor response to current adjuvant and neo-adjuvant treatments (Van Cutsem et al., 2006) . Surgical resection remains the only treatment that can lead to long-term survival, but it is feasible in less than 50% of gastric cancer patients (Van Cutsem et al., 2006) .
The Ras/Raf/Erk mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/AKT (PI3K/AKT) signaling pathways are key oncogenic pathways that are frequently dysregulated in human gastric cancers because of genetic aberrations of key components, leading to their constitutive activation (Michl and Downward, 2005) . Although RAS mutations occur at relatively low frequency in gastric cancers, the MAPK and PI3K/AKT pathways are frequently activated by mechanisms that signal through these pathways, including amplification or overexpression of various receptor tyrosine-kinases and/or their ligands (EGF/EGFR, HGF/c-Met), frequent monoallelic inactivation of phosphatase and tensin homolog and amplification or mutations in AKT1/2 (Michl and Downward, 2005) . Several studies have reported concomitant activation of Wnt/b-catenin and MAPK and/ or PI3K/AKT in human tumors, suggesting that Wnt signaling activation cooperates with these signaling pathways (D'Cruz et al., 2001; Jang et al., 2006; Park et al., 2006; Kim et al., 2007) . For example, conditional expression of oncogenic K-ras in intestinal epithelium of adult mice in the context of Apc-deficient intestinal tumors resulted in a higher number of tumors with greatly accelerated tumor formation leading to reduced life span, in comparison with Apc tumors-expressing wild-type K-ras (Janssen et al., 2006) .
More than 90% of colorectal tumors (colon cancer cells) harbor activating mutations in APC or CTNNB1 (b-catenin) (Morin et al., 1997) . Wnt pathway activation has also been studied in other gastrointestinal tumors such as gastric, small intestinal and esophageal adenocarcinomas. Small intestinal carcinoma is exceedingly rare in humans (Overman, 2009 ) and mutations in APC or CTNNB1 have been found infrequently in these patients (Overman, 2009) as well as in individuals with esophageal adenocarcinoma (Bas et al., 2000) . Conversely, individuals with germ line mutations in APC have increased risk of developing gastric cancer (Giardiello et al., 1993) , and frequent nuclear localization of b-catenin has been observed by immunostaining of such tumors. Some gastric tumors have been shown to contain CTNNB1 or APC mutations (Woo et al., 2001; Clements et al., 2002) . However, the biological impact of Wnt signaling inhibition on the phenotypes of this tumor type is not well established (Caca et al., 1999; Grabsch et al., 2001; Clements et al., 2002; Tomita et al., 2007) . In this study, we sought to extend understanding of mechanisms involved in Wnt pathway activation in human gastric tumor lines as well as biological effects of downregulating the constitutively active Wnt pathway.
Results

Characterization of Wnt pathway aberrations in human gastric cancer cell lines
To assess the frequency and magnitude of constitutive Wnt signaling upregulation in human gastric carcinomas, we screened a series of tumor lines derived from these malignancies for increased levels of uncomplexed b-catenin. An immortalized mammary epithelial cell line, B5/589 (Rubin et al., 1989) and either A427 human lung carcinoma or MEL-888 melanoma, which contain activating b-catenin mutations (Rubinfeld et al., 1997; Sunaga et al., 2001) , served as negative and positive controls in this assay. Figure 1a shows that 4 of 11 gastric tumor lines analyzed, exhibited obviously increased uncomplexed b-catenin levels. To confirm and extend these findings, we measured TCF-dependent transcriptional activity using optimal Tcf-binding site (TOP) containing seven TCF/LEF consensus binding sequence or Far-from optimal Tcf-binding site (FOP), a two base-pair mutant of this sequence, driving enhanced green fluorescent protein or luciferase as the reporters in a lentiviral-based transduction system (Figure 1b ) (Akiri et al., 2009) . A lentivirus expressing enhanced green fluorescent protein under the control of a basal phosphoglycerate kinase promoter served as an infection control. The ratio of TOP/FOP activity determined as mean fluorescence intensity utilizing fluorescenceactivated cell sorting (FACS) with each of the gastric cancer cell lines generally correlated well with their respective levels of uncomplexed b-catenin (Figure 1b ). An example of Wnt signaling activity visualized under the microscope is shown in Figure 1c for a positive (AGS) and negative (SNU-1) tumor line. However, TCF reporter activities observed with one tumor line, N-87, was substantially higher than would have been expected based on the absence of any obvious increase in uncomplexed b-catenin levels in this line (Figures 1a and b) .
Previous reports have characterized some of these gastric tumor lines for Wnt pathway activation. For example, AGS harbors an activating mutation (Caca et al., 1999) (Figure 2a ) and KATO-III, an amplification (Suriano et al., 2005) (Figure 2b ) of CTNNB1 (b-catenin), whereas MKN-28 and MKN-74 contain inactivating mutations of APC (Ikenoue et al., 2002) . To confirm the genetic lesion responsible for Wnt pathway activation in AGS gastric tumor cells, we sequenced CTNNB1 exon 3, which is known to contain activating mutations that prevent its encoded protein from phosphorylations that targets it for proteasome degradation (Morin et al., 1997) . This analysis revealed the activating lesion at codon 34 (Figure 2a) . Amplification of CTNNB1 has been described for KATO-III (Suriano et al., 2005) . Our real time PCR (RT-PCR) analysis revealed that genomic DNA from KATO-III cells contained around 20 copies of this gene. This result is compatible with gene amplification as the mechanism responsible for activation of Wnt signaling in this tumor line (Figure 2b ).
Fearon and colleagues previously identified a CTNNG (g-catenin) mutation in N-87 tumor cells and showed that this mutant activated the Wnt pathway when transfected into recipient cells (Caca et al., 1999) . To confirm and extend these findings, we established N-87-stable TCF-luciferase (TOP/FOP-luciferase) reporter cell lines and tested the effects of small hairpin RNA (shRNA)-mediated knockdown of either b-or g-catenin expression on its TCF reporter activity ( Figure 2c ) along with expression levels of well-characterized TCF target genes, c-Myc (He et al., 1998; van de Wetering et al., 2002) , BMP-4 and Axin-2 (Filali et al., 2002; Jho et al., 2002) by RT-PCR (Supplementary Figure 1) . The effectiveness of b-and g-catenin shRNAs was confirmed by immunoblot analysis (Figure 2d ). Knockdown of g-catenin in N-87 cells markedly reduced TCF reporter activity as well as the expression levels of c-Myc, BMP-4 and Axin-2, known TCF target genes (Po0.05) in a specific manner, whereas b-catenin knockdown had little or no effect under the same conditions ( Figure 2c, Supplementary Figure 1 ). These results demonstrate that the CTNNG mutant identified by Caca et al. (1999) Figure 2B ). These results suggested that some Wntactivated tumors do not depend on this upregulated pathway for proliferation.
To investigate the effect of DNTCF4 on long-term growth inhibition, we subjected mass cultures of AGS, MKN-28 and MKN-74 to a single cycle of DNTCF4 transduction. Although we observed comparable We also observed no effects of DNTCF4 on cell cycle or cell proliferation with a A3008 gastric cell line, which lacked detectable Wnt pathway activation (data not shown).
Sensitivity to Wnt pathway inhibition depends on the level of c-Myc addiction for tumor cell proliferation To investigate possible mechanisms for the inability of DNTCF4 to inhibit MKN-28 or MKN-74 cell proliferation, we compared expression levels of known TCF target genes in these and other Wnt-upregulated tumor lines. In particular, we analyzed c-Myc, which has been shown to exert a central role in the proliferation of colon cancer cells with Wnt pathway activation (He et al., 1998; van de Wetering et al., 2002) . RT-PCR analysis revealed statistically significant reduction in mRNA expression levels (Po0.05) of c-Myc, Axin-2 and Lef-1, another well-documented TCF target genes (Filali et al., 2002; Jho et al., 2002) , in AGS tumor cells transduced with DNTCF4 ( Figure 4c ). There were no obvious differences in the degree of inhibition observed for these target genes in DNTCF4-resistant MKN-28 and MKN-74 as compared with DNTCF4-sensitive 
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Wnt-activated gastric tumors S Asciutti et al tumor lines (Figure 4c ). Of note, basal expression levels of each of these Wnt target genes analyzed were similar in all cell lines tested, as assessed by their respective cycle threshold (Ct) values (data not shown). c-Myc RT-PCR data were confirmed by western blotting, which showed comparable reduction of protein levels in all cell lines transduced with DNTCF4 ( Figure 4d ). Axin-2 and Lef-1 protein levels were too low and/or the available anti-Axin-2 and anti-Lef-1 antibodies not sufficiently sensitive to compare their expression levels with those determined by RT-PCR. Clevers and colleagues have shown that decreased expression of c-Myc led to increased expression of p21(CIP1/WAF1), which mediated cell cycle arrest and differentiation of DLD-1 colon carcinoma cells (He et al., 1998; van de Wetering et al., 2002) . Hence, we also analyzed the expression levels of p21 by immunoblot analysis in DNTCF4-sensitive AGS, and resistant MKN-28 and MKN-74 tumor cells expressing either VECTOR or DNTCF4. The increase in p21 expression associated with reduction in c-Myc (Figure 4d To directly assess whether Wnt-activated gastrointestinal tumor cells refractory to DNTCF4 inhibition were independent of c-Myc-mediated regulation of cell proliferation, we tested the effects of c-Myc downregulation by shRNA on cell cycle profile and proliferation. Although only modest inhibition was observed in DNTCF4-resistant MKN-28 cells, lentiviral-mediated c-Myc shRNA resulted in a striking G1 arrest in DNTCF4-sensitive AGS cells (Figure 5a) . Similarly, c-Myc shRNA induced little inhibition of colony formation by MKN-28 cells, although significantly inhibiting AGS cells under the same conditions (Figure 5b ). The effectiveness of c-Myc shRNA in inducing a comparable inhibition of c-Myc expression in each cell line was confirmed by immunoblot analysis (Figure 5c ). All of these findings established that the refractoriness to DNTCF4 of some Wnt-activated tumors was because of their c-Myc independence for proliferation. Figures 3A and B) . In contrast, both ERK and AKT phosphorylation were readily observed in AGS and MKN-28 tumor lines under the same conditions (Supplementary Figures 3A and B) , whereas MKN-74 tumor cells showed minimal, if any, AKT phosphorylation and very low ERK activation. Thus, these findings could not account for the sensitivity or resistance of Wnt-activated tumor lines to DNTCF4 inhibition of proliferation. We next evaluated the effects of selective downregulation of Wnt signaling or c-Myc alone or in combination with MEK1, or AKT inhibitors in AGS and MKN-28 cells. AGS cells stably infected with one cycle of DNTCF4 or c-Myc shRNA showed significant LY294002, a PI3K inhibitor alone, was growth inhibitory for each tumor line (Po0.05) (Figure 6 ). When either PD98059 or LY294002 treatment was combined with DNTCF4 transduction in AGS cells, the effects on proliferation inhibition were additive at best (Figure 6a) . In striking contrast, combining treatment of either agent with transduction of DNTCF4 or c-Myc shRNA in MKN-28 cells led to comparable and more marked inhibition of proliferation than that observed with the sum of drug treatment and transduction by themselves (Figure 6b ). Synergism was confirmed by analysis of the interaction effects in a two-way ANOVA with Bonferroni's correction (Po0.05) (Slinker, 1998 ) (data not shown). At the concentrations utilized, PD98059 and LY294002 markedly reduced pERK and pAKT, respectively, in each tumor line (Figure 6c ). Significant reduction in the proportion of cells in S-phase was associated with an increased fraction in G1, consistent with a G1 arrest. None of the combinations induced an increase in the subG1 or G2/M population, and we observed no cooperative effects of DNTCF4 with either inhibitor on cell cycle or cell proliferation in gastric cell lines without detectable Wnt pathway activation (data not shown). All of these findings support the concept that certain Wnt-activated tumors can escape c-Myc dependence for proliferation through other oncogenic alterations, which in the case of MKN-28 tumor cells involve ERK and AKT activation.
Discussion
In this study, we characterized Wnt canonical pathway aberrations in human gastric carcinoma lines. In general, we observed a good correlation between pathway activation as detected by increased levels of uncomplexed b-catenin and increased TCF-dependent transcriptional reporter activities in the different tumor lines, some of which have been previously documented as having CTNNB1 or APC mutations (Caca et al., 1999; Ikenoue et al., 2002) . KATO-III gastric tumor cells, which overexpress wild-type CTNNB1 associated with gene amplification (Suriano et al., 2005) , also showed high levels of uncomplexed b-catenin and TCF reporter activity.
A mutation in the g-catenin gene that moderately increases its transcriptional activity was previously identified in N-87 cells (Caca et al., 1999) , suggesting that this could represent an alternative mechanism for Wnt activation in tumors. This hypothesis was supported by data that overexpression of g-catenin stimulated TCF activity, c-Myc expression and cell transformation (Kolligs et al., 2000) . However, later studies provided evidence that g-catenin formed only weak interactions with TCF transcription factors, although it potently stabilized b-catenin and, therefore, acted indirectly to stimulate TCF signaling (Zhurinsky et al., 2000) . Consistent with this model, recent in vitro and in vivo studies revealed that inactivation of the b-catenin gene strongly inhibited the effects of g-catenin on reporter activity and tumor formation (Teuliere et al., 2004; Shimizu et al., 2008) . In this study, we found that knockdown of g-catenin, but not b-catenin, dramatically inhibited TCF signaling in N-87 gastric cancer cells, demonstrating that, in these cells, aberrantly activated g-catenin can stimulate the Wnt pathway in a b-catenin-independent manner.
Thus, Wnt signaling activation in gastric carcinoma lines occurs at reasonably high frequency and involves a wide variety of mechanisms.
Previous studies have correlated reduction in levels of c-Myc, a TCF target gene, with growth inhibition of colon cancer cells (He et al., 1998; van de Wetering et al., 2002) . Similarly, Wnt pathway inhibition by DNTCF4 impaired proliferation of AGS gastric tumor cells associated with a decrease in Myc RNA levels. AGS cells also showed decreased levels of Axin-2 and Lef-1, two other established TCF target genes, (Filali et al., 2002; Jho et al., 2002) in response to DNTCF4. In contrast, MKN-28 and MKN-74 gastric tumor cells appeared not to retain any obvious dependence on Wnt/ b-catenin signaling for proliferation, as we observed no detectable effects of DNTCF4 expression on this phenotype despite the ability of DNTCF4 to comparably inhibit TCF signaling. Of note, levels of c-Myc, a known TCF target gene previously shown to mediate the Wnt proliferation phenotype in colon tumor cells (van de Wetering et al., 2002; Akiri et al., 2009) , were comparably inhibited in the resistant tumor cells associated with increased expression of p21 (CIP1/ WAF1), the growth-suppressive target of c-Myc repression (van de Wetering et al., 2002; Akiri et al., 2009) . Additionally, c-Myc shRNA induced only modest growth inhibitory effects on DNTCF4-resistant MKN-28 cells, corroborating their independence from c-Myc for proliferation. DNTCF4 inhibition of DLD-1 colon cancer cell proliferation has been shown to be mediated by upregulation of the p21 cell cycle inhibitor (van de Wetering et al., 2002; Akiri et al., 2009) . These findings argue that Wnt-activated tumor cells resistant to DNTCF4 induced proliferation inhibition have evolved mechanisms to escape p21 induced growth inhibition.
Previous studies have shown that Wnt-1 or c-myc synergize with H-ras, or K-ras, respectively, in mouse models of mammary tumorigenesis (D'Cruz et al., 2001; Jang et al., 2006) . Of note, ras-driven MAPK activation has been reported to promote progression of around 30% of such tumors to independence of either Wnt-1 or c-myc oncogenes initially required for their growth (Jang et al., 2006) . In our studies, we observed that the presence or absence of constitutive MAPK or PI3K/ AKT activation did not predict Wnt pathway independence for tumor cell proliferation. As a number of gastric carcinomas, including AGS cells possess Ras-activating mutations (Morin et al., 1997) , therapeutic interference with the PI3K/AKT or MAPK signaling pathways has been attempted in efforts to improve survival in patients with such tumors. Unfortunately, the effects of these approaches have been disappointing so far, given the modest improvement in survival (Van Cutsem et al., 2006) . We observed that in DNTCF4-resistant MKN-28 tumor cells with MAPK and/or PI3K/AKT pathway activation, the ability of small molecule antagonists directed against either pathway to inhibit tumor cell proliferation synergized with Wnt pathway inhibition in a c-Myc-dependent manner. These findings support the concept that some Wnt-activated tumors escape c-Myc dependence for proliferation through activation of other oncogenic pathways, whose disruption can cooperate with the antiproliferative effects of Wnt pathway downregulation. In the case of MKN-28 tumor cells, our evidence strongly argues that these oncogenic alterations involve ERK and AKT signaling pathways. The extent that Wnt activation impacts on other biological properties of tumor cells, such as invasiveness or prosurvival signaling, as well as the contribution of known Wnt target genes, such as c-Myc, to such phenotypes should be possible to dissect by analogous approaches.
Materials and methods
Cell culture
Human tumor cell lines, including gastric (KATO-III, N-87, AGS, SNU-1, A3008, SNU-5, OKAJIMA, MKN-74, MKN-28, MKN-7 and KATO-II), lung (A427), melanoma (MEL-888) and the immortalized human renal epithelial cell line (293T) were maintained in either Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, NY, USA) or RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) (20% for KATO-III cells) and 1% penicillin/streptomycin (GIBCO, Carlsbad, CA, USA). The immortalized mammary epithelial cell line B5/589 (Stampfer and Bartley, 1985) was cultured in Dulbecco's modified Eagle's medium as above supplemented with 5 ng/ml hEGF (Peprotech, Rocky Hill, NJ, USA). All cells were cultured at 37 1C in 5% CO 2 .
Analysis of uncomplexed b-catenin and immunoblot analysis GST-E-cadherin binding and immunoblot analysis were performed as previously described (Bafico et al., 1998) . For immunoblot analysis the following primary antibodies were used: phospho and total AKT and ERK1/2 (Cell Signaling, Danvers, MA, USA); a-tubulin (Sigma, St Louis, MO, USA); TCF-4 (Upstate, Lake Placid, NY, USA); c-Myc (Santa Cruz, Santa Cruz, CA, USA); p21, b-and g-catenin (BD Bioscience, San Diego, CA, USA). Anti-mouse IgG or anti-rabbit IgG secondary antibodies conjugated to Alexa Fluor 680 were from Molecular Probes (Eugene, OR, USA). Quantification of signal immunoreactivity was obtained using the Licor Odyssey infrared Imaging system (LI-COR, Lincoln, NE, USA).
Fluorescence-activated cell sorting analysis of TCF-mediated GFP reporter activity Cells infected with TOP or FOP enhanced green fluorescent protein reporter lentiviruses or a lentivirus-expressing GFP from a constitutive phosphoglycerate kinase promoter were trypsinized 4 days after infection, transferred to polystyrene tubes (Falcon, Franklin Lakes, NJ, USA) and subjected to FACS analysis using Cell Quest 3.2 software (Becton Dickinson, San Jose, CA, USA).
Quantification of TCF-mediated luciferase reporter activity
To determine TCF-luciferase reporter activity, cells were transduced with TOP or FOP TCF reporter lentivirusesexpressing firefly luciferase together with renilla luciferase lentivirus (1:20 ratio) used to normalize for infection efficiency.
At 4 days after infection, cells were lysed and analyzed utilizing the dual luciferase reporter assay system (Promega, Madison, WI, USA), according to the manufacturer 0 s instructions. Luciferase reporter activity was calculated by dividing the ratio TOP/RL by the FOP/RL ratio. Results were normalized to the results with vector-transduced cultures. For experiments in which DNTCF4 was used, stable reporter cell lines expressing TOP or FOP TCF luciferase and renilla luciferase were plated in six-well plates at 1 Â 10 5 cells per well. The following day, cells were infected with VECTOR or DNTCF4 lentiviruses, selected with puromycin (2 mg/ml) for 3 days and analyzed for luciferase activity as described above.
FACS analysis of cell cycle profile
For DNA content analysis, cells were trypsinized, combined with floating cells, washed with phosphate-buffered saline and stained with propidium iodide using the CycleTEST Plus DNA reagent kit (Becton Dickinson). Cells were transferred to polystyrene tubes with cell-strainer caps (BD Biosciences) and subjected to FACS analysis using Cell Quest 3.2 software (Becton Dickinson).
Cell growth analysis assay
For colony growth assay, 3 Â 10 4 MKN-28 or MKN-74 cells and 1 Â 10 5 AGS cells were transduced with VECTOR or DNTCF4 lentiviruses, selected with puromycin (2 mg/ml), and seeded in 60-mm plates. At 2 weeks, cells were washed with phosphatebuffered saline, fixed in 10% methanol/acetic acid solution and stained with 1% crystal violet. For experiments in which c-Myc shRNA was used, 2 Â 10 3 AGS or MKN-28 cells were seeded in six-well plates. Experiments were performed at least twice. For some experiments, the specific MEK1 inhibitor PD98059 (2 0 -amino-3 0 -methoxyflavone; Calbiochem, La Jolla, CA, USA) (Alessi et al., 1995) and the specific PI3 kinase inhibitor LY294002 (2-[chloro-4-iodo-phenylamino]-N-cyclopropylmethoxy-3,4-difluoro-benzamide; Cayman, Ann Arbor, MI, USA) (Vlahos et al., 1994) were dissolved in dimethyl sulfoxide (Sigma) at a concentration of 100 mM. Cells were treated with the compounds at a concentration of 40 mM for 36 h and subjected to FACS analysis. We titrated each inhibitor on all cell lines utilizing a range from 1-150 mM and selected 40 mM, as previously reported (Pumiglia and Decker, 1997; Bechard and Dalton, 2009) , as the lowest concentration of each that resulted in efficient downregulation of either pERK or pAKT.
Real time PCR analysis
Total RNAs were extracted from cell lines using Trizol (Invitrogen). Total RNA (5 mg) was reverse transcribed using Superscript II (Invitrogen) and RT-PCR was performed using SYBR Green Mix (Roche, Nutley, NJ, USA) on Stratagene MxPro3005 system. cDNA (50 ng) was amplified and relative mRNA expression levels were quantified using the DDC(t) method (Pfaffl, 2001) . Each reaction was performed in duplicate and results of three independent experiments were used for statistical analysis. Results were normalized to those for TATA binding protein. Primer sequences are given in Supplementary Table S1 .
Statistical analysis
Statistical analysis was performed using unpaired Student's t-test and one-way ANOVA with Bonferroni and Dunnet's correction tests. A two-way-ANOVA with Bonferroni's correction tests was performed to analyze synergism (Slinker, 1998) , A P-value o0.05 was considered statistically significant. All values are given as means ± s.d. of at least three independent experiments.
